Our largest has finally started promoting the CZD story.This...

Our largest has finally started promoting the CZD story.
This from the February newsletter

Calzada Update

In the portfolio we are excited about the upcoming results from Calzada (CZD), with the below from the company’s latest Half Yearly Results:

PolyNovo’s Topical Negative Pressure clinical Trial (“TNP”) (previously referred to as VAC), has progressed well, with the final patient now being treated. Trial results are expected by the end of April 2013 with filing of a 510(k) application seeking FDA clearance to market the product in the USA to follow.

This is what we have been eagerly awaiting and whilst they are a little gory on the eye, I’d encourage you to look at the releases from CZD with photos of the BTM “free flap” trial – the results are spectacular and I believe the technologies being developed at Calzada are second to none.

Should you have any queries in relation the above or the current investments within the Fund, please do not hesitate to contact me or Margot Biggs on 08 9389 3600. This and other past editions of the newsletter will be made available on the website: www.merchantgroup.com.au

http://www.merchantgroup.com.au/news/merchant-opportunities-fund-newsletter-february-2013.html

April not far away